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Abstract
Background: The measurement of complement com-
ponents is clinically useful where a deficiency is sus-
pected, or where excessive activation and consumption 
are present in disease. C2 deficiency carries an increased 
risk of developing systemic lupus erythematosus, recur-
rent infections and atherosclerosis. In this study, we have 
evaluated The Binding Site’s Human Complement C2 
SPAPLUS® assay.
Methods: Linearity was tested using 13 sample dilutions 
covering the standard measuring range. Within- and 
between-assay variabilities were calculated using five 
samples with different C2 concentrations. The correlation 
between C2 concentrations in EDTA-plasma and serum 
was assessed, as was the correlation between C2  meas-
urements by the automated assay and radial immuno-
diffusion. C2 concentrations were compared with CH50 
activity, and quantified in individuals with homozygous 
or heterozygous C2 deficiency, acquired angioedema and 
patients with chronic inflammatory conditions.
Results: The assay was linear across the measuring 
range (3.8–42.3  mg/L). Intra- and interassay variability 
were 2.3%–3.8% and 0%–3.3%, respectively. Comparison 
between C2 measurements in EDTA-plasma and serum pro-
vided a strong correlation (p < 0.0001, R2 = 0.82, slope 0.92), 
as did the correlation between the automated and radial 
immunodiffusion methods (p < 0.0001, R2 = 0.89, slope 
1.07). A positive correlation between C2 concentration and 
CH50 activity was demonstrated (p < 0.0001, R2 = 0.48). 
 Significant differences were observed between the median 
C2 concentrations obtained in healthy controls and the 
patient clinical samples, with homozygous C2-deficient 
patients giving below detectable results.
Conclusions: This C2 SPAPLUS® assay allows the auto-
mated, rapid and precice quantification of complement 
C2 protein and could therefore be considered as a replace-
ment for older, more time-consuming methods.
Keywords: acquired angioedema (AAE); C2; comple-
ment; complement deficiency; hereditary angioedema 
(HAE); SPAPLUS; systemic lupus erythematosus (SLE); 
turbidimetry.
Introduction
The complement cascade is a crucial part of the innate 
immune system and plays a key role in host defense 
against pathogenic infections. There are three conver-
gent complement pathways [classical, alternative and 
mannose-binding lectin (MBL)] that consist of more 
than 30  soluble and membrane-bound proteins [1, 2]. 
These pathways are tightly regulated activation cas-
cades that result in the production of effector molecules 
with diverse biological functions. Complement activa-
tion triggers inflammation by recruiting and activating 
immune cells, promotes the phagocytosis and clearance 
of pathogens through opsonization and can result in 
lysis of pathogen cells through the formation of a mem-
brane attack complex [3, 4]. The complement system 
is also involved in the clearance of apoptotic cells and 
immune complexes and in amplifying adaptive immune 
responses [1, 2, 5].
C2 is one of the key proteins in the classical and MBL 
pathways of complement activation. C2 binds to mem-
brane bound C4b and is subsequently cleaved by C1s 
or MASP2 [6, 7], generating C2b, which is released into 
the fluid phase, and C4bC2a (a C3-convertase). This is a 
crucial and central step in complement activation. Each 
C3 convertase cleaves multiple C3 proteins, resulting in 
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the production of important effector molecules – C3a and 
C3b [2].
The measurement of individual complement proteins 
is clinically important where a deficiency is suspected, or 
where excessive activation and consumption are present 
in disease [8–10]. Homozygous C2 deficiency is the most 
common inherited complement deficiency, with an esti-
mated prevalence of 1 in 10–20,000 in populations of 
European descent [11, 12]. The most frequent C2 deficiency 
is caused by a 28-base pair (bp) deletion in the C2 gene, 
which results in a complete lack of C2 protein synthesis in 
homozygous cases [13]. Although many C2-deficient indi-
viduals appear entirely healthy [12], homozygous C2 defi-
ciency is associated with an increased risk of developing 
systemic lupus erythematosus (SLE) [14, 15], atherosclerosis 
[10] and an increased susceptibility to infections caused by 
encapsulated bacteria such as Streptococcus pneumoniae, 
Neisseria meningitidis or Haemophilus influenzae [16–18].
The measurement of C2 protein concentration is a 
useful tool in aiding the diagnosis of C2 deficiency and a 
key first step in the evaluation of a patient found to have 
reduced or absent classical pathway function. Current 
methods used include electroimmunoassay (EIA) [19] and 
radial immunodiffusion (RID) [20, 21]. These assays have 
proven valuable for the measurement of C2, but there is 
the need for a more automated method. Here we describe 
the characteristics of an automated assay for the meas-
urement of C2 protein concentration on the SPAPLUS® 
 turbidimetric analyzer.
Materials and methods
Plasma and serum samples
Plasma samples were collected by venepuncture into EDTA blood 
collection tubes. For serum samples, blood was collected by 
venepuncture and allowed to clot naturally, after which the serum 
was separated to prevent hemolysis. Where possible, samples were 
tested immediately after collection; otherwise (unless specifically 
stated), they were stored at −20 immediately and subjected to one 
freeze/thaw cycle.
Serum and plasma samples were obtained from several sources 
for these studies.
Analytical study: Samples from healthy adult blood donors (age 
range 19–81 years) were purchased from Quest Biomedical (Solihull, 
UK). Sample collection was approved by the Institution Ethics Review 
Board (#05142), with all donors providing written informed consent. 
These samples were used for assay validation experiments and devel-
opment of the normal adult reference range. Where required, pooled 
samples (from three to five donors) were used to generate samples of 
various C2 concentrations.
Matrix comparison: Residual and anonymous paired EDTA-plasma 
and serum samples from patients referred for immunological investi-
gation (n = 119, age range 0.7–85 years) were obtained from the Immu-
nobiology Clinic of the Erasme Hospital, Belgium. Sample collection 
and use was approved by the Ethics Committee of the Erasme Hospi-
tal, Belgium. Samples were used for the matrix comparison and the 
comparison of C2 protein concentration to CH50 functional activity.
Paired EDTA-Plasma and serum samples were collected from 
consenting healthy adult blood donors at The Binding Site (n = 20, 
age range 25–57 years). These were used to examine the stability of C2 
protein measurements in the two matrices over 3 days.
C2 assay comparison: Serum samples were collected from consent-
ing healthy adult blood donors at The Binding Site (n = 24, age range 
27–47 years).
Anonymous stored serum samples from patients with confirmed 
or suspected C2 deficiency (n = 7, age range 5–64 years) were obtained 
from the Immunodeficiency Centre for Wales.
Both sets of samples were run on the automated C2 assay and 
RID assay.
Clinical study: Serum samples were collected from consenting 
healthy adult blood donors at The Binding Site (n = 20, age range 
25–55 years).
Additional residual and anonymous clinical samples were 
obtained from the Clinical Immunology Service, University of Bir-
mingham (n = 32, age range 28–83 years). Collection of residual sam-
ples and de-identified patient data was approved by the Institution 
Ethics Review Board (REC Reference: RRK4136 and UHB R&D Project 
Reference 2002/201 “Blood donations for use in clinical assays”).
Anonymous stored serum samples from patients with previously 
diagnosed homozygous (n = 4, age range 5–64 years) or heterozygous 
C2 deficiency (n = 1, 20  years) or acquired angioedema (AAE, n = 2, 
age range 65–78  years) were obtained from the Immunodeficiency 
Centre for Wales.
Production of C2 antiserum
C2 isolation from human plasma: C2  was purified from pooled 
 fresh-frozen plasma. Pooled plasma was dialyzed against calcium 
chloride to precipitate the C1 complex, fractionated by sequential 
ammonium sulfate precipitation and ion exchange chromatography 
(SP-Sepharose and Q-Sepharose, GE Healthcare, Chicago, IL, USA), 
and then further purified by size exclusion chromatography (Super-
dex S200, GE Healthcare). Final purity was assessed by SDS-PAGE, 
followed by silver staining or immunoblotting. SDS-PAGE was con-
ducted using 4%–12% NUPAGE® gels (Thermofisher Scientific Inc., 
MA, USA) with a pH 6.0 MOPS running buffer as described in the 
manufacturer’s instructions. Silver staining of the gels was accom-
plished using the Bio-Rad silver stain kit (Bio-Rad, Watford, UK). 
Purified C2 protein was quantified by N-terminal amino acid compo-
sitional analysis (Alta Bioscience, Birmingham, UK).
Conjugated C2 antiserum preparation: Sheep anti-human C2 poly-
clonal antiserum was generated by subcutaneous immunization 
with 150 μg of human C2 antigen mixed with complete Freund’s adju-
vant, and subsequent boosting at monthly intervals with 30 μg anti-
gen in incomplete Freund’s adjuvant. The IgG fraction was isolated 
Brought to you by | Cardiff University
Authenticated
Download Date | 6/7/18 9:42 AM
Tange et al.: Quantification of human complement C2 protein      3
from sheep antiserum by caprylic acid precipitation and was affinity 
purified to specificity using a C2 affinity column (CNBr-Sepharose). 
F(ab’)2 fragments were prepared using pepsin and were conjugated 
to 200 nm carboxyl-modified polystyrene particles with 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride (Thermofisher).
Analytical techniques
C2 concentrations were measured using the automated Human Com-
plement C2 SPAPLUS® assay. CH50 classical pathway activity was 
measured using the CH50 SPAPLUS® assay. Both of these assays are 
automated turbidimetric assays and were run on the SPAPLUS® turbi-
dimeter. For the C2 assay comparison, C2 concentrations were meas-
ured using the automated Human Complement C2 SPAPLUS® assay 
and the Human Complement C2 NL BINDARID™ RID Kit. All assays 
were performed following the manufacturer’s instructions (The Bind-
ing Site Ltd., Birmingham, UK).
Assay validation: Assay validation procedures were adapted from 
the Clinical and Laboratory Standards Institute guidelines. Pooled 
EDTA-plasma samples (usually 3–5 donors/pool) from healthy adult 
blood donors were used. For the assessment of linearity, a high EDTA-
plasma sample pool (54.8 mg/L) was diluted to 13 consecutive lower 
analyte concentrations using a second EDTA-plasma sample pool 
(0.9  mg/L) to cover the measuring range of the assay. Imprecision 
analysis was carried out with five independent samples (7.7, 7.9, 11.5, 
21.2 and 35.2  mg/L). Low-level samples were generated by mixing 
EDTA-plasma with a complement depleted sample pool (heat inac-
tivated for 2 h at 60 °C).
Percentage coefficient of variation (% CV) and standard devia-
tions (SDs) for within-run precision were calculated from 20 indi-
vidual measurements for each sample in a single run. For the other 
precision calculations, each sample was assayed in duplicate, with 
two runs per day over 21 days, giving a total of 84 readings per sam-
ple. Between-batch variability for three different batches, between 
instrument variability across three different instruments, between-
run, between-day and total precision were calculated from the 
84 measurements.
Interference analysis was performed by spiking hemo-
globin (5  g/L), bilirubin (200  mg/L), chyle (1500 FTU), triglyceride 
(1000  mg/dL) or intralipid (500  mg/dL) into EDTA-plasma samples 
with three different C2 concentrations (for hemoglobin, bilirubin 
and chyle: 7.8, 10.4 and 27.8  mg/L; for intralipid and triglyceride; 
7.5, 10.5 and 25.1 mg/L C2). Controls were generated by spiking sam-
ples with equivalent volumes of saline. The assay was deemed to 
have passed the interference assessment if the C2 concentration after 
addition of the potential interfering substances was <± 10% of the 
original value in the control sample.
Normal reference ranges: The reference range was established by 
measuring the C2 concentrations in EDTA-plasma samples taken 
from 120  healthy adult blood donors as mentioned above. These 
results were used to calculate the central 95th percentile range and 
the skewness and kurtosis of the distribution.
Matrix comparison: Paired EDTA-plasma and serum samples were 
analyzed using the turbidimetric C2 assay and compared using 
Bland-Altman and Passing-Bablok analyses. To assess the stability 
of C2 measurements in the two matrices, the 20 paired samples from 
healthy volunteers were run on the C2 SPAPLUS® assay on the day of 
collection, and after 1–3 days storage at 4 °C. Concentrations between 
the matrices were evaluated using Passing-Bablok.
Comparison to CH50 activity: Serum samples were tested for CH50 
complement activity and compared to C2 protein concentration using 
Bland-Altman and Passing-Bablok analyses.
Clinical study: Serum samples from healthy controls (n = 20), 
patients attending the Clinical Immunology Department, Birming-
ham QE Hospital (n = 32), and patients with C2 deficiency (n = 5) or 
acquired angioedema (n = 2) were assayed using the C2 turbidimetric 
assay described above. The patients attending Birmingham QE hos-
pital suffered from a range of conditions including SLE, coeliac dis-
ease and Sjögren’s syndrome.
Statistical analysis
All graphs and statistical analysis were generated using Graph Pad 
Prism statistical software version 5.04. or Analyse-it® for Microsoft 
Excel. The linearity, reference intervals and assay validation calcula-
tions (% CVs and SD) were calculated using Analyse-it. The matrix 
comparison and C2/CH50 results were analyzed using Bland-Altman 
and/or Passing-Bablok analyses (Analyse-it). Differences in the C2 
concentrations between disease groups and healthy controls were 
assessed using Kruskal-Wallis with Dunn’s Multiple Comparison Test 
(Graphpad Prism). A p < 0.05 was considered statistically significant.
Results
Development of antisera
Purity of the C2 antigen was shown by a single band of 
105 kDa on silver stained SDS-PAGE gels and was deemed 
to have >95% purity (Figure 1A). N-terminal sequencing 
Figure 1: Purity of C2 antigen.
Marker (M) or C2 protein (C2) were added to gels and the purity 
of C2 antigen assessed by (A) non-reducing (Nred) SDS-PAGE at 
concentrations of 200 and 500 ng per lane. Silver staining was used 
for detection. (B) 500 ng was analyzed by immunoblotting with the 
antisera indicated (C1 inactivator, C2, or Factor B).
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confirmed C2 identity. The resultant antiserum recognized 
the C2 protein band upon western blotting of human 
plasma. No major contaminating proteins were detected 
in the purified C2 preparation (results shown for Factor 
B and C1 inactivator, Figure 1B). No bands were detected 
with C2-depleted serum (data not shown).
Assay validation
The automated C2 assay was linear between 2.3 and 
54.8 mg/L (y = 1.0 × −0.01, R2 = 0.99), covering the measur-
ing range of 3.8–42.3 mg/L at the standard 1/10 analyzer 
dilution (Figure 2). Assay imprecision was calculated 
between runs, days, batches and instruments (Table 1). 
The within-run and between-run imprecisions for all five 
samples were less than 4%. Between-batch and instru-
ment imprecision were less than 7%, between day <10% 
and total precision <11%. The addition of chyle, hemo-
globin, bilirubin, triglyceride or intralipid caused minimal 
interference with the measurement of C2 protein (Table 2).
C2 protein reference range
The median and mean concentrations in healthy adult 
blood donors (n = 120; 60 males, 60 females) were 30.8 and 
30.6  mg/L, respectively, and the central 95th percentile 
reference interval was 18.9–42.7 mg/L. Skewness and kur-
tosis of the distribution were −0.1 and −0.8, respectively. 
No significant difference was observed between sexes.
Correlation between C2 concentrations 
measured in EDTA-plasma and serum
C2 protein concentrations were measured in 119 matched 
EDTA-plasma and serum samples. There was a strong cor-
relation between the observed concentrations in the two 
matrices (R2 = 0.82, p < 0.0001, y = 1.03 × −0.52 mg/L) with 
a mean negative bias in serum compared to plasma of 
−0.3 mg/L (95% CI −8.4 to 7.8 mg/L) (Figure 3). There was 
98% agreement between the two measurements in clas-
sifying patients as below or above the lower limit of the 
normal range. Sample stability in the two matrices was 
assessed in 20 paired EDTA-plasma and serum samples 
from healthy donors (Supplementary Figure 1). Correla-
tion between the two matrices was very strong where 
samples were assayed directly after collection (R2 = 0.98, 
Figure 2: Linearity of the automated C2 assay.
Thirteen samples were generated by diluting an EDTA-plasma 
sample pool with a high C2 concentration in an EDTA-plasma 
sample pool with a low concentration. Samples were run in tripli-
cate and the mean result for each concentration was plotted against 
the expected C2 concentration.
Table 1: Imprecision of automated SPAPLUS® C2 assay.
Within-run Between-run Between-day Between-batch Between-
instrument
Total precision
% CV SD % CV SD % CV SD % CV SD % CV SD % CV SD
Low 3.2 0.25 2.4 0.18 9.3 0.70 0.7 0.16 3.8 0.89 10.9 0.82
Mid 2.7 0.56 0.0 0.00 4.3 1.01 0.7 0.16 5.9 1.44 5.5 1.31
High 2.7 0.92 1.6 0.56 7.4 2.56 6.2 2.12 5.3 1.80 7.8 2.67
−25% 3.8 0.29 3.2 0.29 6.9 0.64 3.6 0.33 4.9 0.45 8.0 0.74
+25% 2.3 0.27 3.3 0.37 5.3 0.59 2.3 0.25 5.0 0.56 6.7 0.75
Precision was assessed in EDTA-plasma samples with five different C2 concentrations (low, 7.7 mg/L; mid, 21.2 mg/L; high, 35.2 mg/L; 
25% medical decision point, 7.9 mg/L; and +25% medical decision point, 11.5 mg/L). % CV and SD for within-run precision were calculated 
from 20 measurements per sample. For the other precision calculations, each sample was assayed in duplicate, with two runs per day 
over 21 days, giving a total of 84 readings per sample. This part of the study was carried out using three reagent lots and three different 
analyzers.
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Passing and Bablok fit y = 1.0 × +1.0), and slightly weaker 
where samples had been stored for 3 days at 4 °C (R2 = 0.89, 
Passing and Bablok fit y = 1.2 × −1.9).
Correlation between C2 concentrations 
measured using the automated turbidimetric 
and RID assays
The C2 concentrations were measured in 24 healthy con-
trols and seven patients with confirmed or suspected C2 
deficiencies by both the C2 automated turbidimetric and 
RID assays. There was a correlation between the assays 
(R2 = 0.89, p < 0.0001, y = 1.07 × +2.26), with the automated 
assay having a mean positive bias of 4.5  mg/L (95% CI 
−2.5 to 11.5  mg/L) (Figure 4). There was 94% agreement 
between the two assays as classifying individuals above or 
below the lower limit of the respective measuring ranges.
Correlation between C2 concentrations 
and functional complement activity
The C2 concentration in the 119 EDTA-plasma samples 
was compared with CH50 activity in the matched serum 
samples (Figure 5). There was a significant correlation 
between C2 protein concentration and CH50 activity, with 
98.3% agreement in classifying patients as below or above 
the lower limit of the assays normal ranges (p < 0.0001, 
R2 = 0.48, y = 0.6 × −7).
Clinical study – C2 concentrations in various 
clinical samples
The C2 concentration was quantified in samples from an 
independent group of normal healthy controls, patients 
with homozygous or heterozygous C2 deficiency, AAE, SLE 
and other clinical samples from patients with chronic, 
inflammatory conditions such as coeliac disease and 
Sjögren’s syndrome. The independent group of normal 
healthy controls validated the adult normal reference 
range. Significant differences were observed between 
the median C2 concentrations obtained in the normal 
controls and both the patients with homozygous C2 defi-
ciency (p < 0.01) and the inflammatory patient group 
(p < 0.0001) (Figure 6). Both AAE patients had C2 con-
centrations below the normal reference range (18.8 mg/L 
and 6.8  mg/L), whereas the heterozygous C2-deficient 
individual had a C2 concentration within, but at the lower 
end, of the normal reference range (25.5 mg/L). In the SLE 
cohort, nine patients had normal concentrations of C2, 
two patients had concentrations below (9.2 and 6.6 mg/L) 
Table 2: Interference data for C2 automated assay.
Chyle Bilirubin Hemoglobin Triglyceride Intralipid
Low −0.57 −2.51 1.43 1.38 8.03
MDP −0.92 −3.33 2.42 7.90 −1.28
Normal range 1.15 −5.46 −0.32 −0.16 5.15
ETDA-plasma samples with three different C2 concentrations were 
spiked with one of the five interferents or saline as a control. 
Samples tested include one low concentration sample, one around 
the medical decision point (MDP) and one within the normal range 
(for hemoglobin, bilirubin and chyle: 7.8, 10.4 and 27.8 mg/L; for 
intralipid and triglyceride; 7.5, 10.5 and 25.1 mg/L). All samples 
were then run in the SPAPLUS® C2 assay. Values represent percent-
age change observed in the presence of the interfering substances.
Figure 3: Comparison of the C2 concentration measured in EDTA-plasma and serum samples.
The C2 concentration was measured in 119 matched serum and EDTA-plasma samples. The comparison between the two matrices was 
assessed using (A) Passing-Bablok analysis (identity line shown where y = x) and (B) Bland-Altman analysis (solid line demonstrates the 
mean difference and broken lines show the limits of agreement, −1.96 and +1.96 SDs).
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and two  patients had concentrations above (52.8 and 
69.6 mg/L) the normal reference range.
Discussion
In the present study, we have developed an automated 
C2 assay for use on the SPAPLUS® turbidimetric analyzer. 
We produced C2-specific antisera using purified intact C2 
antigen as it is known that the fragments of the protein 
can be structurally diverse from the parent molecule. The 
method used here has enabled the rapid, precise and quan-
titative determination of C2 protein concentration over a 
wide measuring range, a range likely to be encountered in 
clinical practice. The automated C2 assay was linear over 
the range 2.3−54.8 mg/L at the standard sample dilution 
and was unaffected by common blood constituents which 
might interfere in the assay.
A major consideration when measuring complement 
proteins and their activation products is that complement 
activation can occur ex vivo. EDTA inhibits complement 
activation, so EDTA-plasma is often considered a more 
stable matrix than serum for complement evaluations 
Figure 5: Correlation between C2 concentration and functional 
CH50 activity.
The C2 concentration (EDTA-Plasma) and CH50 activities (serum) 
were quantified in 119 matched patient samples. Results were ana-
lyzed using Passing-Bablok analysis.
Figure 6: C2 concentrations in clinical samples.
The C2 concentration was quantified in serum samples from 
normal, healthy controls (n = 20), homozygous C2-deficient patients 
(C2 homo, n = 4), a heterozygous C2-deficient individual (C2 hetero, 
n = 1), acquired angioedema patients (AAE, n = 2), systemic lupus 
erythematosus patients (SLE, n = 13) and other clinical samples from 
a referral population with chronic, inflammatory conditions (n = 19). 
Dotted lines demonstrate the upper and lower limits of the normal 
range. **p < 0.01, ****p < 0.0001.
Figure 4: Comparison of the C2 concentration measured by the C2 SPAPLUS® assay and RID.
The C2 concentration was measured by both the C2 SPAPLUS® assay and RID in 24 healthy controls and seven individuals with confirmed or 
suspected C2 deficiency. The comparison between the two methods was assessed using (A) Passing-Bablok analysis (identity line shown 
where y = x) and (B) Bland-Altman analysis (solid line demonstrates the mean difference and broken lines show the limits of agreement, 
−1.96 and +1.96 SDs).
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[22,  23]. The comparison of C2 protein concentrations 
measured in EDTA-plasma and serum samples here 
demonstrates a high level of agreement between the two 
matrices for this assay. There are four samples outside the 
Bland-Altman established criteria. These samples could 
not be assayed on the day of collection, so this may be due 
to the stability of C2 measurements in serum. Indeed, in 
the assessment of stability in the two matrices performed 
here, the correlation did weaken slightly after storage of 
samples. The manufacturer’s recommendation is that 
serum may be used to measure C2 concentrations in this 
assay where samples will be processed and tested on the 
day of collection, but where this cannot be guaranteed, 
EDTA-plasma is the more suitable matrix.
A number of laboratories are using techniques such 
as electroimmunoassay to measure C2 concentrations 
[19]. This technique can be laborious and time consum-
ing, and the interpretation of results is potentially subjec-
tive, requiring trained staff to carry out the analyses. The 
assay we have described here is automated, simple and 
has a quick time to first result. The assay has also fulfilled 
criteria for linearity, precision and interference, which are 
based on those suggested by the Clinical Laboratory and 
Standards Institute, making it an attractive alternative to 
other available methods. The automated C2 assay shows 
a significant correlation with CH50 activity, and with C2 
concentrations measured by the traditional RID method.
Using healthy adult blood donors, we developed a 
95th percentile reference interval of 18.9–42.7  mg/L and 
validated it with an independent group of healthy samples. 
All four patients with previously determined genetic C2 
deficiency had a C2 concentration of <3.8 mg/L. Patient 1 
and patient 2  had the most common C2 deficiency, with 
a confirmed homozygous 28-bp deletion. Both of these 
patients, as would be expected, had abnormal CH50 
results but normal AP50 activities. The individual with 
a heterozygous C2 deficiency had 25.5 mg/L C2, which is 
within but at the lower end of the normal range. Testing a 
larger cohort of heterozygous patients on this assay is nec-
essary to establish a potential range of C2 concentrations 
in heterozygous-deficient individuals.
Measuring C2 concentrations is important in the eval-
uation of patients with a reduced CH50 test result, and in 
the assessment of potential homozygous and heterozy-
gous C2 deficiency. The measurement of C2 may also have 
a utility in patients with SLE and is reduced in hereditary 
and acquired angioedema. Here we have shown that the 
two AAE patients tested had C2 concentrations below 
the normal reference range. These individuals were also 
known to have low C4 concentrations (0.02 g/L and <0.01 
g/L, respectively). Donaldson and Rosen [24] demonstrated 
that C2 and C4, but not C3, were completely diminished 
in patients with hereditary angioedema (HAE) during an 
attack. Following recovery these levels increased, but 
still remained low. Patients with HAE or AAE related to C1 
inhibitor have absent or reduced levels of C1 inhibitor, or 
have protein which does not function normally. This leads 
to uncontrolled activation of the complement and contact 
systems. Patients suffer from uncontrolled, sometimes 
life-threatening, episodes of edema, which can be treated 
if correctly diagnosed, and prophylactic medications pre-
scribed if attacks are severe and recurrent. Low levels of 
C2 and C4 with normal C3 concentrations are highly char-
acteristic of HAE [25], with C4 measurements often used as 
a front line test, as it is simple test and readily available. 
More recently, it has been shown that C4 can be normal 
in a small proportion of HAE patients (including those on 
therapy) [26, 27], so it would be interesting to study C2 in 
these individuals.
It has also been shown that C2 expression can be 
abnormal in autoimmune disease. Here, 2/13  serum 
samples from SLE patients had C2 concentrations <50% 
below the lower limit of the reference range and 2/13 had 
concentrations above the upper limit of the reference 
range. Soter et  al. [28] demonstrated that the early clas-
sical pathway components (C1, C4 and C2) were often 
depressed in sera from individuals with rheumatoid 
arthritis (RA), Sjögren’s syndrome or SLE. On the other 
hand, Firestein et al. [29] showed that C2 messenger RNA 
was increased in the synovium of patients with RA, and 
this correlated with the degree of synovial inflammation. 
In our study, 31% of SLE patients had serum C2 concentra-
tions outside of the normal reference range, with patients 
exhibiting both reduced and elevated levels. Complement 
proteins are acute phase proteins, and their expression 
is increased in certain inflammatory conditions. Further-
more, homozygous and heterozygous C2 deficiencies are 
associated with increased incidence of SLE [30]. Our data 
suggest that in some SLE patients tested, there is an acute 
phase response, as indicated by the elevated C2 levels. 
A simple automated assay to measure C2 may aid in the 
evaluation of these patients.
One of the key limitations of this study is that the 
normal range could not be assessed in pediatric samples. 
Immunodeficiency is often tested in children less than 
3 years of age, so future studies developing the normal ref-
erence intervals for C2 in this age-group would be useful. 
There are, however, previous studies looking at C2 levels 
in infants using RID techniques. Davis et al. [31] demon-
strated in 10 infants at 1 month old and 10 infants aged 
6 months that the C2 concentrations were comparable to 
that found in adults.
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In conclusion, we have developed a simple, auto-
mated assay that can measure C2 protein concentration in 
plasma and serum samples. C2 concentrations in disease 
have not yet been as extensively studied as other comple-
ment proteins, such as C3 and C4, but the development 
of this simple, rapid and reliable method will provide the 
platform for such future studies.
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